Score Pharma

Score Pharma, Inc. is a preclinical-stage biotechnology company founded in May 2018 and headquartered in Huntsville, Alabama. The company focuses on developing more potent, second-generation antibody therapeutics by improving existing, clinically validated monoclonal antibody (mAb) products. The core of its operation is the proprietary CoreX technology, a process that uses cell culture additives to create afucosylated biobetter antibody therapeutics. This method enhances the Antibody-Dependent Cellular Cytotoxicity (ADCC) response, which is crucial for eliminating cancer cells, by strengthening the bond between immune cells and cancer cells targeted by the antibody.

The company was founded by Bruce Jones, who serves as President and CEO and is the inventor of the proprietary process technology, along with co-founders Steven Feder and Martina Molsbergen. Dr. Jones has over 30 years of experience in the pharmaceutical and biopharmaceutical industry, having directed drug discovery at companies like Cephalon and Regeneron. The business model is to develop these enhanced therapeutics to a Phase 1 clinical stage and then out-license them for further development, which leverages existing markets and increases the probability of success. Score Pharma's initial therapeutic focus is on oncology, prioritizing treatments for non-Hodgkin lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), and HER2-positive breast cancer.

As a virtual biotech, Score Pharma utilizes strategic partnerships and a distributed team to advance its pipeline. The company has received backing from investors including gBETA and The Innovation Space and was awarded funds from Southern Research as part of the Innovate Alabama Tax Credits initiative. By transforming existing therapies, the company aims to de-risk the drug development process and accelerate the time-to-market for more effective treatments.

Keywords: antibody therapeutics, ADCC enhancement, biotechnology, oncology, monoclonal antibodies, CoreX technology, preclinical stage, drug development, out-licensing, biobetter therapeutics, cancer therapy, non-Hodgkin lymphoma, Chronic Lymphocytic Leukemia, HER2-positive breast cancer, afucosylation, biopharmaceutical, immunotherapy, drug discovery, cell culture additive, virtual biotech